A cross-sectional web survey study to clarify reality of EGPA related symptoms in patients with eosinophilic granulomatosis with polyangiitis (KUNPU study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050230186

Enrollment

200

Registered

2024-02-22

Start date

2024-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic granulomatosis with polyangiitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Informed consent on the website 2. Females and males aged >=18 years at time of enrollment 3. History of physician-diagnosed EGPA more than 1 year ago and those who have been receiving treatment before enrollment

Exclusion criteria

Exclusion criteria: No exclusion criteria is set for this web survey.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with EGPA with each EGPA related symptom by severity	—

Secondary

Measure	Time frame
1. Proportion of patients with EGPA by total number of EGPA related symptoms according to the 13 items 2. Proportion of patients with EGPA by most painful symptom 3. Proportion of patients with EGPA with each EGPA related symptom by severity in EGPA relapse Proportion of patients with EGPA by total number of EGPA related symptoms according to the 13 items in EGPA relapse Proportion of most painful symptom among symptoms of patients with EGPA in EGPA relapse 4. Proportion of patients with EGPA with EGPA related daily trouble	—

Measure

Time frame

1. Proportion of patients with EGPA by total number of EGPA related symptoms according to the 13 items 2. Proportion of patients with EGPA by most painful symptom 3. Proportion of patients with EGPA with each EGPA related symptom by severity in EGPA relapse Proportion of patients with EGPA by total number of EGPA related symptoms according to the 13 items in EGPA relapse Proportion of most painful symptom among symptoms of patients with EGPA in EGPA relapse 4. Proportion of patients with EGPA with EGPA related daily trouble

—

Contacts

Public ContactHitomi Uchimura

AstraZeneca K.K.

hitomi.uchimura@astrazeneca.com+81-6-4802-3600

Outcome results